Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva maintains initial forecasts

Teva maintains initial forecasts

8th May 2008

Israeli pharmaceutical firm Teva has maintained the forecast it made at the start of the year about its projected operational progress during 2008.

Teva described its business as having had a strong start to the year, with its MS treatment Copaxone singled out for its particularly impressive market performance.

Overall, the company generated around £1,286 million worth of sales revenues during the first three months of this year, which represented an increase of close to 24 per cent compared to the same period of 2007.

“We have already made great progress in implementing our new strategy,” said Teva’s president and chief executive Shlomo Yanai.

“During the first quarter, we significantly increased investments in research and development and operations in order to support our growth plans,” he added.

Teva recently revealed that the sales of its Copaxone product had reached record levels during the first quarter of this year and were worth 35 per cent more than in the same quarter a year ago.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.